


\*in mucosal or acral melanoma or melanoma associated with sunlight

The Standard category is based on current treatment indications with approved funding by the Spanish National Health System The **Recommended** category is based on current recommendations by EMEA and FDA

- Martín-Algarra S, Fernández-Figueras MT, López-Martín JA, at al; Spanish Society of Pathology; Spanish Society of Medical Oncology. Guidelines for biomarker testing in metastatic 1. melanoma: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol. 2014 Apr;16(4):362-73. doi: 10.1007/s12094-013-1090-5.
- Scherrer E, Rau R, Lorenzi M, Shui I, Townson S, Larkin J. Systematic literature review for the association of biomarkers with efficacy of anti-PD-1 inhibitors in advanced 2. melanoma. Future Oncol. 2021 Mar 30. doi: 10.2217/fon-2021-0154..
- Mao L, Dai J, Cao Y, et al. Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathway. Eur J Cancer. 2021 Mar 23;148:297-306. doi: 3. 10.1016/j.ejca.2021.02.021.



Cátedra de Medicina Personalizada de Precisión

UAM Universidad Autónoma de Madrid

